Summary
36.17 0.12(0.33%)10/04/2024
Longboard Pharmaceuticals Inc (LBPH)
Longboard Pharmaceuticals Inc (LBPH)
Key Facts
1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
0.47 | 13.14 | 1.92 | 3.55 | 95.94 | 689.74 | 0.00 | 272.89 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
Trading Data | ||
Close | 36.17 | |
Open | 35.50 | |
High | 37.58 | |
Low | 35.21 | |
Volume | 1,741,305 | |
Change | 0.17 | |
Change % | 0.47 | |
Avg Volume (20 Days) | 751,307 | |
Volume/Avg Volume (20 Days) Ratio | 2.32 | |
52 Week Range | 3.60 - 43.15 | |
Price vs 52 Week High | -16.18% | |
Price vs 52 Week Low | 904.72% | |
Range | 1.89 | |
Gap Up/Down | -1.92 |
Fundamentals | ||
Market Capitalization (Mln) | 1,214 | |
EBIDTA | 0 | |
PE Ratio | 0.0000 | |
PEG Ratio | 0.0000 | |
WallStreet Target Price | 29.75 | |
Book Value | 6.6200 | |
Earnings Per Share | -2.6210 | |
EPS Estimate Current Quarter | -0.4800 | |
EPS Estimate Next Quarter | -0.5500 | |
EPS Estimate Current Year | -1.7500 | |
EPS Estimate Next Year | -2.1000 | |
Diluted EPS (TTM) | -2.6210 | |
Revenues | ||
Profit Marging | 0.0000 | |
Operating Marging (TTM) | 0.0000 | |
Return on asset (TTM) | 0.0000 | |
Return on equity (TTM) | 0.0000 | |
Revenue TTM | 0 | |
Revenue per share TTM | 0.0000 | |
Quarterly Revenue Growth (YOY) | 0.0000 | |
Quarterly Earnings Growth (YOY) | 0.0000 | |
Gross Profit (TTM) | 0 |
Dividends | ||
Dividend Share | 0.0000 | |
Dividend Yield | ||
Valuations | ||
Trailing PE | 0.0000 | |
Forward PE | 0.0000 | |
Price Sales (TTM) | 0.0000 | |
Price Book (MRQ) | 0.9190 | |
Revenue Enterprise Value | 0.0000 | |
EBITDA Enterprise Value | 0.3415 | |
Shares | ||
Shares Outstanding | 13,586,000 | |
Shares Float | 5,602,047 | |
Shares Short | 0 | |
Shares Short (Prior Month) | 0 | |
Shares Ratio | 0.00 | |
Short Outstanding (%) | 0.00 | |
Short Float (%) | 0.00 | |
Insider (%) | 31.85 | |
Institutions (%) | 67.79 |
10/04 16:01 EST - businesswire.com
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to three new employees. The Compensation Committee of the Board of Directors of Longboard approved the grants of non-qualified stock options to purchase an aggregate of 56,000 shares of its common stock (the “Common Stock”) and 35,000 restricted.
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to three new employees. The Compensation Committee of the Board of Directors of Longboard approved the grants of non-qualified stock options to purchase an aggregate of 56,000 shares of its common stock (the “Common Stock”) and 35,000 restricted.
09/26 08:30 EST - businesswire.com
Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin in Dravet Syndrome
LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it has initiated its global Phase 3 DEEp SEA Study evaluating its investigational drug bexicaserin for the treatment of seizures associated with Dravet syndrome in participants two years of age and older. “We are thrilled to announce the initiation of our global Phase 3.
Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin in Dravet Syndrome
LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it has initiated its global Phase 3 DEEp SEA Study evaluating its investigational drug bexicaserin for the treatment of seizures associated with Dravet syndrome in participants two years of age and older. “We are thrilled to announce the initiation of our global Phase 3.
09/20 14:36 EST - zacks.com
Longboard Stock Soars on FDA Designations for Epilepsy Drug
The FDA grants orphan drug and rare pediatric disease designations to LBPH's lead pipeline drug for the treatment of Dravet Syndrome.
Longboard Stock Soars on FDA Designations for Epilepsy Drug
The FDA grants orphan drug and rare pediatric disease designations to LBPH's lead pipeline drug for the treatment of Dravet Syndrome.
08/26 09:00 EST - businesswire.com
Longboard Pharmaceuticals to Host Investor & Analyst Event in New York on September 16, 2024
LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will host an Investor & Analyst Event which will feature updates for the planned global Phase 3 Program evaluating bexicaserin (LP352), a first-in-class 5-HT2C receptor superagonist in development for the treatment of seizures associated with Developmental and Epi.
Longboard Pharmaceuticals to Host Investor & Analyst Event in New York on September 16, 2024
LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will host an Investor & Analyst Event which will feature updates for the planned global Phase 3 Program evaluating bexicaserin (LP352), a first-in-class 5-HT2C receptor superagonist in development for the treatment of seizures associated with Developmental and Epi.
08/04 13:39 EST - seekingalpha.com
Longboard Pharmaceuticals, Inc. (LBPH) Q2 2024 Earnings Call Transcript
Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH ) Q2 2024 Earnings Call Transcript August 1, 2024 4:30 PM ET Company Participants Brandi Roberts - Executive Vice President and Chief Financial Officer Kevin Lind - President and Chief Executive Officer Randall Kaye - Executive Vice President and Chief Medical Officer Conference Call Participants Laura Chico - Wedbush Securities Joel Beatty - Baird Gavin Clark-Gartner - Evercore Kalpit Patel - B. Riley Securities David Hoang - Citigroup Yatin Suneja - Guggenheim Securities Operator Good afternoon, ladies and gentlemen, and welcome to the Longboard Pharmaceuticals Earnings and Corporate Update Call.
Longboard Pharmaceuticals, Inc. (LBPH) Q2 2024 Earnings Call Transcript
Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH ) Q2 2024 Earnings Call Transcript August 1, 2024 4:30 PM ET Company Participants Brandi Roberts - Executive Vice President and Chief Financial Officer Kevin Lind - President and Chief Executive Officer Randall Kaye - Executive Vice President and Chief Medical Officer Conference Call Participants Laura Chico - Wedbush Securities Joel Beatty - Baird Gavin Clark-Gartner - Evercore Kalpit Patel - B. Riley Securities David Hoang - Citigroup Yatin Suneja - Guggenheim Securities Operator Good afternoon, ladies and gentlemen, and welcome to the Longboard Pharmaceuticals Earnings and Corporate Update Call.
08/01 16:01 EST - businesswire.com
Longboard Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported second quarter 2024 financial results. “The first half of the year has been monumental for Longboard and underpins the vision that we have been working towards since the inception of the Company, which is to help a broad range of patients living.
Longboard Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported second quarter 2024 financial results. “The first half of the year has been monumental for Longboard and underpins the vision that we have been working towards since the inception of the Company, which is to help a broad range of patients living.
07/29 09:15 EST - businesswire.com
Longboard Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host Corporate Update Call on August 1
LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it plans to release second quarter 2024 financial results and provide a corporate update, including topline Phase 1 SAD data for LP659, its centrally acting, highly selective sphingosine-1-phosphate (S1P) receptor modulator, on August 1, 2024. The Company will host a con.
Longboard Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host Corporate Update Call on August 1
LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it plans to release second quarter 2024 financial results and provide a corporate update, including topline Phase 1 SAD data for LP659, its centrally acting, highly selective sphingosine-1-phosphate (S1P) receptor modulator, on August 1, 2024. The Company will host a con.
07/25 09:50 EST - zacks.com
Longboard Pharmaceuticals (LBPH) Is a Great Choice for 'Trend' Investors, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Longboard Pharmaceuticals (LBPH) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Longboard Pharmaceuticals (LBPH) Is a Great Choice for 'Trend' Investors, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Longboard Pharmaceuticals (LBPH) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
07/23 07:00 EST - fool.com
3 Russell 2000 Growth Stocks That Could Be Worth the Risk
Interest rate cuts may could provide a major catalyst for Russell 2000 listed stocks. These three Russell 2000 constituents warrant a serious look by growth investors right now.
3 Russell 2000 Growth Stocks That Could Be Worth the Risk
Interest rate cuts may could provide a major catalyst for Russell 2000 listed stocks. These three Russell 2000 constituents warrant a serious look by growth investors right now.
07/09 10:56 EST - zacks.com
Wall Street Analysts Think Longboard Pharmaceuticals (LBPH) Could Surge 43.7%: Read This Before Placing a Bet
The mean of analysts' price targets for Longboard Pharmaceuticals (LBPH) points to a 43.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Think Longboard Pharmaceuticals (LBPH) Could Surge 43.7%: Read This Before Placing a Bet
The mean of analysts' price targets for Longboard Pharmaceuticals (LBPH) points to a 43.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
07/09 09:51 EST - zacks.com
Longboard Pharmaceuticals (LBPH) is on the Move, Here's Why the Trend Could be Sustainable
If you are looking for stocks that are well positioned to maintain their recent uptrend, Longboard Pharmaceuticals (LBPH) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Longboard Pharmaceuticals (LBPH) is on the Move, Here's Why the Trend Could be Sustainable
If you are looking for stocks that are well positioned to maintain their recent uptrend, Longboard Pharmaceuticals (LBPH) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
07/03 09:41 EST - benzinga.com
Top 3 Health Care Stocks That May Crash This Quarter
As of July 3, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Top 3 Health Care Stocks That May Crash This Quarter
As of July 3, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
07/02 10:26 EST - zacks.com
Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag
Longboard (LBPH) gains 14% as the FDA grants the Breakthrough Therapy designation to its investigational epilepsy treatment candidate, bexicaserin, for patients aged two years or older.
Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag
Longboard (LBPH) gains 14% as the FDA grants the Breakthrough Therapy designation to its investigational epilepsy treatment candidate, bexicaserin, for patients aged two years or older.
07/01 09:00 EST - businesswire.com
Longboard Pharmaceuticals Receives Breakthrough Therapy Designation for Bexicaserin (LP352)
LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that the FDA has granted Breakthrough Therapy designation for its investigational drug bexicaserin for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs) for patients two years of age or older. “We are thrilled to receive Breakthroug.
Longboard Pharmaceuticals Receives Breakthrough Therapy Designation for Bexicaserin (LP352)
LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that the FDA has granted Breakthrough Therapy designation for its investigational drug bexicaserin for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs) for patients two years of age or older. “We are thrilled to receive Breakthroug.
06/10 09:00 EST - businesswire.com
Longboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)
LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #5HT2--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced positive interim results from its ongoing 52-week open-label extension of the PACIFIC Study evaluating bexicaserin (LP352) in participants ages 12-65 years old with Developmental and Epileptic Encephalopathies. “We are thrilled to see a sustained, durable response in seizure.
Longboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)
LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #5HT2--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced positive interim results from its ongoing 52-week open-label extension of the PACIFIC Study evaluating bexicaserin (LP352) in participants ages 12-65 years old with Developmental and Epileptic Encephalopathies. “We are thrilled to see a sustained, durable response in seizure.
05/02 16:01 EST - businesswire.com
Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates
LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported first quarter 2024 financial results. “I am extremely encouraged by the totality of the bexicaserin data generated to date. The recently presented late-breaking data from the PACIFIC Study at AAN continues to support the potential of bexicaserin.
Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates
LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported first quarter 2024 financial results. “I am extremely encouraged by the totality of the bexicaserin data generated to date. The recently presented late-breaking data from the PACIFIC Study at AAN continues to support the potential of bexicaserin.
04/03 09:00 EST - businesswire.com
Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15
LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that Dr. Randall Kaye, Longboard's Chief Medical Officer, will present late-breaking data from the PACIFIC Study evaluating bexicaserin, an oral, centrally acting 5-HT2C receptor superagonist, in participants with Developmental and Epileptic Encephalopathies (DEEs) at the AAN.
Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15
LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that Dr. Randall Kaye, Longboard's Chief Medical Officer, will present late-breaking data from the PACIFIC Study evaluating bexicaserin, an oral, centrally acting 5-HT2C receptor superagonist, in participants with Developmental and Epileptic Encephalopathies (DEEs) at the AAN.